reference standard raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
=== Human use === Nitrofurazone was previously available as a prescription in the U.S., and was indicated as a topical solution, topical cream, or topical ointment for the treatment of bacterial skin infections, wounds, burns, and ulcers. It was also used as a prophylactic measure to prevent infection that could potentially result in skin graft rejection. Nitrofurazone is still very popular as a topical solution for the treatment of tonsillitis in Russia.
== History == In the Standard Model (SM), matter stability is described by assigning a baryon number B=+1 to the proton (lightest baryon), following Hermann Weyl's 1929 proposed conservation principle. Ernst Stueckelberg formally postulated the baryon number (heavy charge at the time) conservation law in 1939. In the 1950s it was realized that limits on proton decay were exceedingly long. The very existence of advanced life forms on Earth implied
== Diagnostic advantages == Due to PCT's variance between microbial infections and healthy individuals, procalcitonin has become a marker to improve identification of bacterial infection and guide antibiotic therapy. The table below is a summary from Schuetz, Albrich, and Mueller, summarizing the current data of selected, relevant studies investigating PCT in different types of infections. Legend: ✓ = Moderate evidence in favor of PCT ✓✓ = Good evidence in favor of PCT ✓✓✓ = Strong evidence in favor of PCT ~ = Evidence in favor or against the use of PCT, or still undefined
Returning American strike pilots generally assessed these carriers as more crippled than they actually were, mistaking for devastating direct hits what Japanese post-war records revealed to have actually been huge geysers caused by near misses. The battleship Haruna was also hit by two bombs, including one directly on a main battery turret. Damage was contained, and she was able to keep station because her captain promptly called to flood the turret's magazine to avoid the possibility of an explosion. Twenty American aircraft in the strike were destroyed by Japanese fighters and anti-aircraft fire that made up for a relative lack of accuracy with high volume of fire. After the protracted strike, it became clear that most of the aircraft returning to their carriers were running dangerously low on fuel, and to worsen matters, night had fallen. At 20:45, the first returning U.S. aircraft reached TF 58. Knowing his aviators would have difficulty finding their carriers, Admiral Joseph J. Clark of Hornet decided to illuminate his carrier, shining searchlights directly up into the night, despite the risk of attack from Japanese submarines and night-flying aircraft. Mitscher backed up the decision, and soon every ship in Task Force 58 was lit up, in spite of the risks involved. Picket destroyers fired starshells to help the aircraft find the task groups. Planes were given clearance to land on any available flight deck (not just their home carriers, as usual), and many did land on other carriers. Despite this, 80 of the returning aircraft were lost.
As the leader of the Cure Alzheimer's Fund's Alzheimer's Genome Project, Tanzi several other AD genes, most notably, CD33, reported in 2008 with Lars Bertram, in the American Journal of Human Genetics. In that study, Tanzi reported the first family-based genome-wide association study of AD, which most notably to the identification of the first innate immune microglial AD gene, CD33, which encodes a cell-surface receptor on monocytes and microglia. In 2013, Tanzi and Dr. Ana Griciuc first reported in Neuron that increased expression of CD33 in microglial cells in AD brain and showed that a protective CD33 gene variant was associated with reductions in CD33 expression and Abeta levels in AD brain. Importantly, they showed CD33 inhibits microglial phagocytosis and clearance of Abeta and induces pro-inflammatory cytokine release leading to neuroinflammation. They also elucidated the molecular mechanism by which sialic acid binds to CD33 to induce neuroinflammation. In a follow-up study published in Neuron in 2019, Tanzi and Griciuc compared the neuroinflammatory effects of the CD33 gene to another AD-associated innate immune gene, TREM2. Knockout of CD33 in AD mice attenuated amyloid-beta pathology and improved cognition while knockout of TREM2 led to opposite effects. They then showed that TREM2 functions downstream of CD33 and that crosstalk between CD33 and TREM2 involves the neuroinflammation-related IL-1beta/IL-1RN axis cluster.
Sources: en.wikipedia.org
On arriving at Paris three days after Waterloo, Napoleon still clung to the hope of a concerted national resistance; but the temper of the legislative chambers, and of the public generally, did not favour his view. Lacking support Napoleon abdicated again on 22 June 1815, and on 15 July he surrendered to the British squadron at Rochefort. The Allies exiled him to the remote South Atlantic island of Saint Helena, where he died on 5 May 1821. In Italy, Joachim Murat, whom the Allies had allowed to remain King of Naples after Napoleon's initial defeat, once again allied with his brother-in-law, triggering the Neapolitan War (March to May 1815). Hoping to find support among Italian nationalists fearing the increasing influence of the Habsburgs in Italy, Murat issued the Rimini Proclamation inciting them to war. The proclamation failed and the Austrians soon crushed Murat at the Battle of Tolentino (2–3 May 1815), forcing him to flee. The Bourbons returned to the throne of Naples on 20 May 1815. Murat tried to regain his throne, but after that failed, he was executed by firing squad on 13 October 1815. The Second Treaty of Paris, signed on 20 November 1815, officially marked the end of the Napoleonic Wars.
=== MeSH D12.644.360 – intracellular signaling peptides and proteins === MeSH D12.644.360.011 – activating transcription factor 6 MeSH D12.644.360.024 – adaptor proteins, signal transducing MeSH D12.644.360.024.264 – caveolin 1 MeSH D12.644.360.024.272 – caveolin 2 MeSH D12.644.360.024.280 – cortactin MeSH D12.644.360.024.295 – crk-associated substrate protein MeSH D12.644.360.024.297 – grb2 adaptor protein MeSH D12.644.360.024.298 – grb7 adaptor protein MeSH D12.644.360.024.300 – grb10 adaptor protein MeSH D12.644.360.024.301 – interferon-stimulated gene factor 3 MeSH D12.644.360.024.301.500 – interferon-stimulated gene factor 3, alpha subunit MeSH D12.644.360.024.301.500.500 – stat1 transcription factor MeSH D12.644.360.024.301.500.750 – stat2 transcription factor MeSH D12.644.360.024.301.750 – interferon-stimulated gene factor 3, gamma subunit MeSH D12.644.360.024.303 – interferon regulatory factors MeSH D12.644.360.024.303.124 – interferon regulatory factor-1 MeSH D12.644.360.024.303.249 – interferon regulatory factor-2 MeSH D12.644.360.024.303.374 – interferon regulatory factor-3 MeSH D12.644.360.024.303.437 – interferon regulatory factor-7 MeSH D12.644.360.024.303.500 – interferon-stimulated gene factor 3, gamma subunit MeSH D12.644.360.024.305 – pii nitrogen regulatory proteins MeSH D12.644.360.024.307 – paxillin MeSH D12.644.360.024.311 – protein inhibitors of activated STAT MeSH D12.644.360.024.313 – 14-3-3 proteins MeSH D12.644.360.024.318 – proto-oncogene proteins c-crk MeSH D12.644.360.024.326 – proto-oncogene proteins c-vav MeSH D12.644.360.024.334 – smad proteins MeSH D12.644.360.024.334.200 – smad proteins, inhibitory MeSH D12.644.360.024.334.200.600 – smad6 protein MeSH D12.644.360.024.334.200.700 – smad7 protein MeSH D12.644.360.024.334.500 – smad proteins, receptor-regulated MeSH D12.644.360.024.334.500.100 – smad1 protein MeSH D12.644.360.024.334.500.200 – smad2 protein MeSH D12.644.360.024.334.500.300 – smad3 protein MeSH D12.644.360.024.334.500.500 – smad5 protein MeSH D12.644.360.024.334.500.800 – smad8 protein MeSH D12.644.360.024.334.750 – smad4 protein MeSH D12.644.360.024.342 – stat transcription factors MeSH D12.644.360.024.342.100 – stat1 transcription factor MeSH D12.644.360.024.342.200 – stat2 transcription factor MeSH D12.644.360.024.342.300 – stat3 transcription factor MeSH D12.644.360.024.342.400 – stat4 transcription factor MeSH D12.644.360.024.342.500 – stat5 transcription factor MeSH D12.644.360.024.342.600 – stat6 transcription factor MeSH D12.644.360.024.374 – suppressor of cytokine signaling proteins MeSH D12.644.360.024.500 – tumor necrosis factor receptor-associated peptides and proteins MeSH D12.644.360.024.500.500 – tnf receptor-associated factor 1 MeSH D12.644.360.024.500.750 – tnf receptor-associated factor 2 MeSH D12.644.360.024.500.875 – tnf receptor-associated factor 3 MeSH D12.644.360.024.500.937 – tnf receptor-associated factor 5 MeSH D12.644.360.024.500.968 – tnf receptor-associated factor 6 MeSH D12.644.360.050 – adenylate cyclase MeSH D12.644.360.075 – apoptosis regulatory proteins MeSH D12.644.360.075.311 – apoptosis inducing factor MeSH D12.644.360.075.405 – caspases MeSH D12.644.360.075.405.200 – caspase 1 MeSH D12.644.360.075.437 – inhibitor of apoptosis proteins MeSH D12.644.360.075.437.500 – neuronal apoptosis-inhibitory protein MeSH D12.644.360.075.437.750 – x-linked inhibitor of apoptosis protein MeSH D12.644.360.075.718 – proto-oncogene proteins c-bcl-2 MeSH D12.644.360.075.718.100 – bcl-associated death protein MeSH D12.644.360.075.718.400 – bcl-2-associated x protein MeSH D12.644.360.075.718.750 – bcl-2 homologous antagonist-killer protein MeSH D12.644.360.075.718.937 – bcl-x protein MeSH D12.644.360.075.718.968 – bh3 interacting domain death agonist protein MeSH D12.644.360.100 – ca(2+)-calmodulin dependent protein kinase MeSH D12.644.360.100.500 – myosin-light-chain kinase MeSH D12.644.360.150 – casein kinases MeSH D12.644.360.150.300 – casein kinase i MeSH D12.644.360.150.300.100 – casein kinase ialpha MeSH D12.644.360.150.300.200 – casein kinase idelta MeSH D12.644.360.150.300.300 – casein kinase iepsilon MeSH D12.644.360.150.600 – casein kinase ii MeSH D12.644.360.200 – cyclic nucleotide-regulated protein kinases MeSH D12.644.360.200.125 – cyclic amp-dependent protein kinases MeSH D12.644.360.200.125.500 – beta-adrenergic receptor kinase MeSH D12.644.360.200.150 – cyclic gmp-dependent protein kinases MeSH D12.644.360.200.575 – protamine kinase MeSH D12.644.360.250 – cyclin-dependent kinases MeSH D12.644.360.250.067 – cdc2-cdc28 kinases MeSH D12.644.360.250.067.249 – cdc2 protein kinase MeSH D12.644.360.250.067.500 – cdc28 protein kinase, s cerevisiae MeSH D12.644.360.250.067.875 – cyclin-dependent kinase 5 MeSH D12.644.360.250.067.900 – cyclin-dependent kinase 9 MeSH D12.644.360.250.323 – cyclin-dependent kinase 2 MeSH D12.644.360.250.451 – cyclin-dependent kinase 4 MeSH D12.644.360.250.515 – cyclin-dependent kinase 6 MeSH D12.644.360.250.580 – maturation-promoting factor MeSH D12.644.360.250.580.500 – cdc2 protein kinase MeSH D12.644.360.275 – eif-2 kinase MeSH D12.644.360.287 – focal adhesion protein-tyrosine kinases MeSH D12.644.360.300 – glycogen synthase kinases MeSH D12.644.360.300.500 – glycogen synthase kinase 3 MeSH D12.644.360.325 – gtp-binding protein regulators MeSH D12.644.360.325.150 – gtpase-activating proteins MeSH D12.644.360.325.150.100 – chimerin proteins MeSH D12.644.360.325.150.100.200 – chimerin 1 MeSH D12.644.360.325.150.300 – eukaryotic initiation factor-5 MeSH D12.644.360.325.150.500 – ras gtpase-activating proteins MeSH D12.644.360.325.150.500.460 – neurofibromin 1 MeSH D12.644.360.325.150.500.500 – p120 gtpase activating protein MeSH D12.644.360.325.150.750 – rgs proteins MeSH D12.644.360.325.225 – guanine nucleotide dissociation inhibitors MeSH D12.644.360.325.300 – guanine nucleotide exchange factors MeSH D12.644.360.325.300.200 – eukaryotic initiation factor-2b MeSH D12.644.360.325.300.300 – guanine nucleotide-releasing factor 2 MeSH D12.644.360.325.300.450 – proto-oncogene proteins c-vav MeSH D12.644.360.325.300.600 – ral guanine nucleotide exchange factor MeSH D12.644.360.325.300.700 – ras guanine nucleotide exchange factors MeSH D12.644.360.325.300.700.500 – ras-grf1 MeSH D12.644.360.325.300.700.700 – son of sevenless proteins MeSH D12.644.360.325.300.700.700.600 – son of sevenless protein, drosophila MeSH D12.644.360.325.300.700.700.630 – sos1 protein MeSH D12.644.360.350 – guanylate cyclase MeSH D12.644.360.375 – heterotrimeric gtp-binding proteins MeSH D12.644.360.375.100 – gtp-binding protein alpha subunits MeSH D12.644.360.375.100.100 – gtp-binding protein alpha subunits, g12-g13 MeSH D12.644.360.375.100.200 – gtp-binding protein alpha subunits, gi-go MeSH D12.644.360.375.100.200.500 – gtp-binding protein alpha subunit, gi2 MeSH D12.644.360.375.100.300 – gtp-binding protein alpha subunits, gq-g11 MeSH D12.644.360.375.100.400 – gtp-binding protein alpha subunits, gs MeSH D12.644.360.375.520 – gtp-binding protein beta subunits MeSH D12.644.360.375.730 – gtp-binding protein gamma subunits MeSH D12.644.360.375.940 – transducin MeSH D12.644.360.376 – i-kappa b kinase MeSH D12.644.360.378 – i-kappa b proteins MeSH D12.644.360.381 – intracellular calcium-sensing proteins MeSH D12.644.360.381.249 – calmodulin MeSH D12.644.360.381.311 – calnexin MeSH D12.644.360.381.374 – calreticulin MeSH D12.644.360.381.437 – gelsolin MeSH D12.644.360.381.500 – neuronal calcium-sensor proteins MeSH D12.644.360.381.500.124 – guanylate cyclase-activating proteins MeSH D12.644.360.381.500.249 – hippocalcin MeSH D12.644.360.381.500.374 – Kv channel-interacting proteins MeSH D12.644.360.381.500.500 – neurocalcin MeSH D12.644.360.381.500.750 – recoverin MeSH D12.644.360.400 – map kinase kinase kinases MeSH D12.644.360.400.100 – map kinase kinase kinase 1 MeSH D12.644.360.400.200 – map kinase kinase kinase 2 MeSH D12.644.360.400.300 – map kinase kinase kinase 3 MeSH D12.644.360.400.400 – map kinase kinase kinase 4 MeSH D12.644.360.400.500 – map kinase kinase kinase 5 MeSH D12.644.360.400.800 – proto-oncogene proteins c-mos MeSH D12.644.360.400.842 – raf kinases MeSH D12.644.360.400.842.249 – oncogene proteins v-raf MeSH D12.644.360.400.842.374 – proto-oncogene proteins b-raf MeSH D12.644.360.400.842.500 – proto-oncogene proteins c-raf MeSH D12.644.360.440 – mitogen-activated protein kinase kinases MeSH D12.644.360.440.100 – map kinase kinase 1 MeSH D12.644.360.440.200 – map kinase kinase 2 MeSH D12.644.360.440.300 – map kinase kinase 3 MeSH D12.644.360.440.400 – map kinase kinase 4 MeSH D12.644.360.440.500 – map kinase kinase 5 MeSH D12.644.360.440.600 – map kinase kinase 6 MeSH D12.644.360.440.700 – map kinase kinase 7 MeSH D12.644.360.450 – mitogen-activated protein kinases MeSH D12.644.360.450.169 – extracellular signal-regulated map kinases MeSH D12.644.360.450.169.500 – mitogen-activated protein kinase 1 MeSH D12.644.360.450.169.750 – mitogen-activated protein kinase 3 MeSH D12.644.360.450.169.875 – mitogen-activated protein kinase 6 MeSH D12.644.360.450.169.937 – mitogen-activated protein kinase 7 MeSH D12.644.360.450.340 – jnk mitogen-activated protein kinases MeSH D12.644.360.450.340.500 – mitogen-activated protein kinase 8 MeSH D12.644.360.450.340.750 – mitogen-activated protein kinase 9 MeSH D12.644.360.450.340.800 – mitogen-activated protein kinase 10 MeSH D12.644.360.450.835 – p38 mitogen-activated protein kinases MeSH D12.644.360.450.835.200 – mitogen-activated protein kinase 11 MeSH D12.644.360.450.835.400 – mitogen-activated protein kinase 12 MeSH D12.644.360.450.835.600 – mitogen-activated protein kinase 13 MeSH D12.644.360.450.835.800 – mitogen-activated protein kinase 14 MeSH D12.644.360.525 – monomeric gtp-binding proteins MeSH D12.644.360.525.100 – adp-ribosylation factors MeSH D12.644.360.525.100.100 – ADP-ribosylation factor 1 MeSH D12.644.360.525.400 – rab gtp-binding proteins MeSH D12.644.360.525.400.025 – rab1 gtp-binding proteins MeSH D12.644.360.525.400.050 – rab2 gtp-binding protein MeSH D12.644.360.525.400.100 – rab3 gtp-binding proteins MeSH D12.644.360.525.400.100.100 – rab3a gtp-binding protein MeSH D12.644.360.525.400.150 – rab4 gtp-binding proteins MeSH D12.644.360.525.400.200 – rab5 gtp-binding proteins MeSH D12.644.360.525.450 – ral gtp-binding proteins MeSH D12.644.360.525.462 – ran gtp-binding protein MeSH D12.644.360.525.475 – rap gtp-binding proteins MeSH D12.644.360.525.475.100 – rap1 gtp-binding proteins MeSH D12.644.360.525.500 – ras proteins MeSH D12.644.360.525.500.300 – oncogene protein p21(ras) MeSH D12.644.360.525.500.600 – proto-oncogene proteins p21(ras) MeSH D12.644.360.525.700 – rho gtp-binding proteins MeSH D12.644.360.525.700.050 – cdc42 gtp-binding protein MeSH D12.644.360.525.700.050.500 – cdc42 gtp-binding protein, saccharomyces cerevisiae MeSH D12.644.360.525.700.100 – rac gtp-binding proteins MeSH D12.644.360.525.700.100.100 – rac1 gtp-binding protein MeSH D12.644.360.525.700.200 – rhoa gtp-binding protein MeSH D12.644.360.525.700.300 – rhob gtp-binding protein MeSH D12.644.360.543 – olfactory marker protein MeSH D12.644.360.562 – phosphatidylethanolamine binding protein MeSH D12.644.360.581 – phospholipase c gamma MeSH D12.644.360.600 – ribosomal protein s6 kinases MeSH D12.644.360.600.249 – ribosomal protein s6 kinases, 70-kda MeSH D12.644.360.600.500 – ribosomal protein s6 kinases, 90-kda
In the fields of medicine, biotechnology, and pharmacology, drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered by identifying the active ingredient from traditional remedies or by serendipitous discovery, as with penicillin. More recently, chemical libraries of synthetic small molecules, natural products, or extracts were screened in intact cells or whole organisms to identify substances that had a desirable therapeutic effect in a process known as classical pharmacology. After sequencing of the human genome allowed rapid cloning and synthesis of large quantities of purified proteins, it has become common practice to use high-throughput screening of large compound libraries against isolated biological targets which are hypothesized to be disease-modifying in a process known as reverse pharmacology. Hits from these screens are then tested in cells and then in animals for efficacy. Modern drug discovery involves the identification of screening hits, medicinal chemistry, and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy and potency, metabolic stability (to increase the half-life), and oral bioavailability. Once a compound that fulfills all of these requirements has been identified, the process of drug development can continue. If successful, clinical trials are developed.
==== Interactions with other nephrotoxins ==== Another area of controversy and uncertainty is whether and to what extent vancomycin increases the toxicity of other nephrotoxins. Clinical studies have yielded various results, but animal models indicate that the nephrotoxic effect probably increases when vancomycin is added to nephrotoxins such as aminoglycosides. A dose- or serum level-effect relationship has not been established.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.